Covered recipient · General Payments record
TAMARA N PLATNER
Physician Assistants & Advanced Practice Nursing Providers Physician Assistant
General Payments · PY2022–2024
$751.66
- Reported across 39 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $343.36 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $70.14 | 4 |
| ABBVIE INC. | $63.17 | 3 |
| Biogen, Inc. | $56.76 | 3 |
| Merz Pharmaceuticals, LLC | $55.86 | 2 |
| Teva Pharmaceuticals USA, Inc. | $35.16 | 2 |
| ARGENX US, INC. | $23.15 | 1 |
| MITSUBISHI TANABE PHARMA AMERICA, INC. | $20.31 | 1 |
| Kedrion Biopharma, Inc. | $18.81 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $20.88 | 01/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108024182 | CMS |
| ABBVIE INC. | $23.63 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108024184 | CMS |
| ABBVIE INC. | $18.66 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108024186 | CMS |
| ARGENX US, INC. | $23.15 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142149614 | CMS |
| Biogen, Inc. | $16.82 | 07/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104831498 | CMS |
| Biogen, Inc. | $19.37 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104848984 | CMS |
| Biogen, Inc. | $20.57 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104844360 | CMS |
| Kedrion Biopharma, Inc. | $18.81 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125861524 | CMS |
| Lilly USA, LLC | $18.06 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135961971 | CMS |
| Lilly USA, LLC | $16.93 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135893977 | CMS |
| Lilly USA, LLC | $16.99 | 11/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135961973 | CMS |
| Lilly USA, LLC | $18.16 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135958875 | CMS |
| Merz Pharmaceuticals, LLC | $29.14 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137959982 | CMS |
| Merz Pharmaceuticals, LLC | $26.72 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137959984 | CMS |
| MITSUBISHI TANABE PHARMA AMERICA, INC. | $20.31 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144512741 | CMS |
| Teva Pharmaceuticals USA, Inc. | $18.11 | 09/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151696159 | CMS |
| Teva Pharmaceuticals USA, Inc. | $17.05 | 09/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151696167 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.